TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05445271

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Optic nerve sheath diameter measurement with linear ultrasound
Description: In this study, we aimed to show whether endotracheal intubation or LMA applications with optic nerve sheath diameter measurement, which is a completely non-invasive method, have effects on intracranial pressure.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Optic nerve sheath diameter measurement with linear ultrasound
Description: In this study, we aimed to show whether endotracheal intubation or LMA applications with optic nerve sheath diameter measurement, which is a completely non-invasive method, have effects on intracranial pressure.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Optic nerve sheath diameter measurement with linear ultrasound
Description: In this study, we aimed to show whether endotracheal intubation or LMA applications with optic nerve sheath diameter measurement, which is a completely non-invasive method, have effects on intracranial pressure.
Study: NCT06459206

Intervention type: DEVICE
Intervention: Pulse oximeter
Description: Devices (4) were placed on the finger base and the fingertip of two right or left fingers and placed in motion for the duration of the study. Devices (3) were placed on the contralateral side and maintained motionless for the duration of the of study. Blood samples were taken at each stable level of oxygenation.
Study: NCT05111041

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: #EnufSnuff.TXT- First Responder
Description: Participants in this intervention will be given the choice of following the Gradual Reduction to Quit program or to choose their own quit date within 2-4 weeks. The Gradual Reduction to Quit program will reduce smokeless tobacco use via text message support and weekly prompts guiding the participants to gradually decrease their use of smokeless tobacco until they are down to zero. A four week Nicotine Replacement Therapy (NRT) sample in the form of lozenges will also be provided to all participants. The intent of this program is to reduce the number of times participants use smokeless tobacco.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enough Snuff Intervention
Description: Participants will be sent the Enuf Snuff cessation manual, support text messages, as well as a four week Nicotine Replacement Therapy (NRT) sample in the form of lozenges.
Study: NCT05050942

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAM2029
Description: CAM2029 (octreotide subcutaneous depot) 20 mg will be administered every 2 weeks as a subcutaneous injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Octreotide LAR
Description: Octreotide LAR 30 mg will be administered every 4 weeks as an intramuscular injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lanreotide ATG
Description: Lanreotide ATG 120 mg will be administered every 4 weeks as a deep subcutaneous injection
Study: NCT06476574

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vacuum-formed retainer
Description: * After patient finishes orthodontic treatment, the fixed orthodontic appliance will be debonded; finishing and polishing of the enamel surface will be done.~* An alginate impression will be taken to be poured into a working model for fabrication of the Vacuum-formed retainer; 1mm Hard vacuum sheet will be used.~* The retainer will be finished and delivered to the patient.~* The patient will be instructed to wear the retainer night time only and to contact us if any damage occurred to the retainers for immediate replacement; and he will be supplied with a check list to evaluate the compliance and to calculate the wearing hours.~* Another alginate impression will be taken for fabrication of the study model which will later be scanned to obtain the digital model at T0; and a periodontal chart will be filled to record the periodontal status at T0 (before wearing of the retainer).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Combined Vacuum-formed and Lingual bonded retainer from canine-to-canine.
Description: * A multistrand rectangular stainless steel retainer wire will be bonded to the lingual surface of the lower anterior teeth, from the canine-to-canine bonded to all six anteriors; followed by an alginate impression; the impression will be poured into a working model for fabrication of the Vacuum-formed retainer; 1mm Hard vacuum sheet will be used \& it will be finished and delivered to the patient.~* The patient will be instructed to wear the Vacuum retainer night time only and to contact us if any damage occurred to the retainers for immediate replacement or rebonding of the detached parts of the bonded retainer; and will be supplied with a check list to evaluate the compliance and to calculate the wearing hours.~* Another alginate impression will be taken (with the bonded retainer in place) for fabrication of the study model which will later be scanned to obtain the digital model at T0; and a periodontal chart will be filled to record the periodontal status at T0.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lingual bonded retainer from canine-to-canine
Description: * After patient finishes orthodontic treatment, the fixed orthodontic appliance will be debonded; finishing and polishing of the enamel surface will be done.~* A multistrand rectangular stainless steel retainer wire will be bonded to the lingual surface of the lower anterior teeth, from the canine-to-canine bonded to all six anteriors.~* The patient will be instructed to contact us if any damage occurred to the retainers for immediate replacement or rebonding of the detached parts of the retainer.~* An alginate impression will be taken (with the bonded retainer in place) for fabrication of the study model which will later be scanned to obtain the digital model at T0; and a periodontal chart will be filled to record the periodontal status at T0 (at the same visit of the delivery of the bonded retainer).
Study: NCT06325618

Intervention type: OTHER
Intervention: No intervention other than obtaining biopsies
Description: Skin, fat, and muscle biopsies will be obtained

Intervention type: OTHER
Intervention: No intervention other than obtaining biopsies
Description: Skin, fat, and muscle biopsies will be obtained

Intervention type: DRUG
Intervention: Indocyanine green (ICG)
Description: Indocyanine green will be injected to evaluate the lymphatic system.

Intervention type: DRUG
Intervention: Indocyanine green (ICG)
Description: Indocyanine green will be injected to evaluate the lymphatic system.
Study: NCT06418217

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Exercise and Patient Education
Description: Patients will undergo a 12-week physiotherapist-led exercise program consisting of 8 supervised sessions and home-based training in between.~Patients will keep training diaries, where each session is tracked in regards of completed repetitions and pain before and after the sessions. Each session will consist of four exercises.
Study: NCT04769050

Intervention type: DRUG
Intervention: Docetaxel combined with Trastuzumab±Pertuzumab
Description: Docetaxel, 75 mg/m2 ivgtt d1 q3w Trastuzumab, 6 mg/kg(8 mg/kg for initial dose) ivgtt d1 q3w Pertuzumab, 420mg(840mg for initial dose) ivgtt d1 q3w

Intervention type: DRUG
Intervention: T-DM1 or Capecitabine combined with Pyrotinib regimen.
Description: T-DM1, 3.6mg/kg(8 mg/kg for initial dose) ivgtt d1 q3w Capecitabine, 1250 mg/m2 bid po d1-14 q3w Pyrotinib, 400mg po daily (continuously)
Study: NCT04784897

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brilacidin
Description: Brilacidin IV infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of Care (SoC)
Description: SoC therapies for COVID-19

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Standard of Care (SoC)
Description: SoC therapies for COVID-19
Study: NCT06494215

Intervention type: OTHER
Group type: OTHER
Intervention: Pressure Support Variation and Calculation of Respiratory Mechanics
Description: Patients will be submitted to different levels of pressure support (PS) in a randomly assigned order. First 30 minutes shall be recorded at the clinical PS. Next, blood gas samples shall be collected. Subsequently, three inspiratory pauses of at least 2 seconds shall be performed with an interval of at least 8 respiratory cycles between them. The same shall be performed with three expiratory pauses. Next, the PS shall be varied to 50% less or 50% more than clinical PS (based on randomization) and the same procedures shall be performed after 30 minutes of data recording (blood gas sample collection, inspiratory and expiratory pauses). All data shall be analyzed offline using a software that will be able to compare three different methods to calculate Pendelluft magnitude based on the literature. After completion of the protocol, ventilatory parameters shall be returned to the original settings. If the patient becomes tachypneic during lower PS, the protocol shall be interrupted.
Study: NCT05197036

Intervention type: PROCEDURE
Intervention: Total Knee Arthroplasty
Description: A surgical procedure to replace both the tibial and femoral articular surfaces with titanium prostheses.

Intervention type: PROCEDURE
Intervention: Total Knee Arthroplasty
Description: A surgical procedure to replace both the tibial and femoral articular surfaces with titanium prostheses.
Study: NCT06047847

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: TOTUM-448
Description: The study is divided in two phases. The first clinical phase of the project is aimed at determining TOTUM-448's metabolites absorption peak (two galenic forms will be tested: capsules and powder). Then, human circulating metabolites from polyphenols will be quantified and characterized by ultra-high performance liquid chromatography hyphenated with tandem mass spectrometry (UPLC-MS/MS). Once the absorption profile is characterized, volunteers will visit once again the clinical center for the collection of serum fractions either naïve (before ingestion) or enriched (containing circulating metabolites following TOTUM-448 ingestion). The enriched fraction (circulating bioactive collection) will be collected at t-max as characterized in the first phase (absorption profil's peak). Finally, biological activity of TOTUM-448 on human hepatocytes will be studied by comparing naïve serum and serum containing circulating metabolites according to an in vitro protocol.
Study: NCT06235450

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iLIDS100
Description: Subject applies iLIDS accessory to the iTEAR100 device. Applies to Eyelid margin similar to commercial products
Study: NCT06470009

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Portable Neuromodulation Stimulator (PoNS)
Description: The PoNS device does not deliver stimulation produced by amplitude-controlled, biphasic pulses to the anterior superior surface of the tongue through gold-plated electrodes plus physical therapy.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Portable Neuromodulation Stimulator (PoNS)
Description: The PoNS device delivers stimulation produced by amplitude-controlled, biphasic pulses to the anterior superior surface of the tongue through gold-plated electrodes plus physical therapy.
Study: NCT06210854

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pBI-11
Description: HPV16/18 vaccine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: pBI-11
Description: HPV16/18 vaccine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pBI-11
Description: HPV16/18 vaccine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: pBI-11
Description: HPV16/18 vaccine
Study: NCT06556147

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VXB-241 60 mcg (Low Dose)
Description: VXB-241 low dose, single, IM injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VXB-241 60 mcg (Low Dose)
Description: VXB-241 low dose, single, IM injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VXB-241 120 mcg (Medium Dose)
Description: VXB-241 medium dose, single, IM injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VXB-241 120 mcg (Medium Dose)
Description: VXB-241 medium dose, single, IM injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VXB-241 240 mcg (Medium-high Dose)
Description: VXB-241 medium-high dose, single, IM injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VXB-241 240 mcg (Medium-high Dose)
Description: VXB-241 medium-high dose, single, IM injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VXB-241 480 mcg (High Dose)
Description: VXB-241 high dose, single, IM injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VXB-241 480 mcg (High Dose)
Description: VXB-241 high dose, single, IM injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VXB-241
Description: VXB-241 dose to be decided based on Year-1 results, single, IM injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VXB-241
Description: VXB-241 dose to be decided based on Year-1 results, single, IM injection.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, single, IM injection.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo, single, IM injection.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo, single, IM injection.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo, single, IM injection.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo, single, IM injection.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, single, IM injection.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Arexvy 120 mcg
Description: Arexvy 120 mcg, single, IM injection.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Arexvy 120 mcg
Description: Arexvy 120 mcg, single, IM injection.
Study: NCT06557148

Intervention type: DIAGNOSTIC_TEST
Intervention: 18F-Fluoroestradiol PET/CT
Description: Scanned at baseline and again posttreatment within 2 weeks of the restaging FDG PET/CT
Study: NCT04291469

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Probiotics（Live combined bifidobacteria, lactobacillus and maltodextrin tables)
Description: The probiotic compound will consist of tables containing approximately 10\^9 colony forming units of the probiotic organisms, Lactobacillus and Bifidobacteria lactis strain，mixed maltodextrin(oral, daily for 14 weeks).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Prebiotics (Combined inulin and maltodextrin tables)
Description: The prebiotic compound will consist of tables containing inulin and maltodextrin (oral,daily for 14 weeks)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: maltodextrin
Description: Maltodextrin tables (oral,daily for 14 weeks)
Study: NCT06038604

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychosocial Support Intervention
Description: Participants will receive six weekly 60-minute sessions conducted by videoconference.
Study: NCT05989802

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Oral swab molecular testing
Description: Swab-based testing provides a non-invasive approach to collect respiratory specimens for TB testing. Data in adults suggests that swab-based testing could be valuable when sputum collection is not feasible or available.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Automated Cough Sound Analysis
Description: Cough sounds can be collected through a mobile phone and tablet, and then analyzed with machine learning algorithms to predict TB.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Automated Lung Sound Analysis
Description: Lung sounds can be collected with a non-invasive digital stethoscope, and then saved on a tablet or phone and analyzed by machine learning algorithms to predict TB.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chest X Ray Computer Aided Detection
Description: Several artificial intelligence algorithms have been developed to predict TB, though this has not yet been validated in children.
Study: NCT06394596

Intervention type: OTHER
Intervention: Prognostic factors affecting graft survival
Description: The primary outcome measured was a 5-year graft survival, defined as the absence of any need for dialysis or re-transplantation five years following the initial transplantation
Study: NCT06473883

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training recommendation
Description: The players in the intervention group are also given specific training recommendations for the prevention of head injuries, which are compiled by experts (sports scientists, physiotherapists and neuroscientists). The exercise selection covers several areas that can be affected after a head injury. Each section contains 8 different exercises with increasing levels of difficulty (3x Basic-3x Intermediate-2x Advanced). The recommendations should be used as a warm-up program throughout the season before each training session. The coach or athletic coach will lead the warm-up program and ensure that each player follows the sequence and completes each phase according to the scheduled weeks. The warm-up program should be conducted as an 8-week cycle.
Study: NCT06333912

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: dental implant placement with ridge splitting.
Description: ridge splitting to increase bone width in atrophic maxilla with simultaneous implant placement

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: dental implant placement with ridge splitting.
Description: ridge splitting to increase bone width in atrophic maxilla with simultaneous implant placement
Study: NCT06072053

Intervention type: PROCEDURE
Intervention: Burr Hole Craniostomy and Postoperative Exhaustive Drainage Strategy
Description: According to the preoperative CT results, drilling and drainage was performed at the thickest level of the hematoma; during the operation, the hematoma cavity was adequately flushed with saline and a drainage tube was left in the hematoma cavity; after the operation, the hematoma cavity was flushed with urokinase, and the drainage tube was removed after adequate drainage.

Intervention type: PROCEDURE
Intervention: YL-1 puncture needle and Postoperative Exhaustive Drainage Strategy
Description: Based on preoperative CT, the thickest level of the hematoma was selected and localized. During the operation, an electric drilling needle was used to rapidly break through the skull and dura to enter the cavity of the subdural hematoma, and the puncture needle was fixed to the skull to drain the subdural hematoma. After the operation, the hematoma cavity was flushed with urokinase, and the drainage tube was removed after adequate drainage.
Study: NCT05361707

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tasimelteon Oral Capsule, Tasimelteon Liquid Suspension
Description: Once Daily
Study: NCT04873050

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide Pen Injector [Ozempic]
Description: Start injection of semaglutide 0.25mg subcutaneously (SC) once a week for 4 weeks; step up to 0.5 mg SC QD for once a week for 4 weeks to a final dose of 1.0 mg semaglutide SQ weekly for 24 doses

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Placebo semaglutide pen injector
Description: Start injection of placebo semaglutide 0.25mg subcutaneously (SC) one a week for 4 weeks; step up to 0.5 mg SC QD for once a week for 4 weeks to a final dose of 1.0 mg semaglutide SQ weekly for 24 doses
Study: NCT05022394

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sapanisertib
Description: Given PO
Study: NCT05221905

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BEET IT - Concentrate Beet root juice
Description: Beet It Sport (James White Drinks, Ltd.) each containing 400mg of inorganic nitrate (\~6.5 mmol) will be consumed twice daily (totalling \~13 mmol of inorganic nitrate per day) for at least 2 days prior to testing visits, as well as 2 hours prior to testing visits.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BEET IT - Concentrate Beet root juice
Description: Beet It Sport (James White Drinks, Ltd.) each containing 400mg of inorganic nitrate (\~6.5 mmol) will be consumed twice daily (totalling \~13 mmol of inorganic nitrate per day) for at least 2 days prior to testing visits, as well as 2 hours prior to testing visits.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: BEET IT - Concentrate Beet root juice
Description: Beet It Sport (James White Drinks, Ltd.) each containing 400mg of inorganic nitrate (\~6.5 mmol) will be consumed twice daily (totalling \~13 mmol of inorganic nitrate per day) for at least 2 days prior to testing visits, as well as 2 hours prior to testing visits.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BEET IT - Concentrate Beet root juice (nitrate depleted)
Description: Beet It Sport (James White Drinks, Ltd.) each containing 0mg of inorganic nitrate (\~0 mmol) will be consumed twice daily (totalling \~0 mmol of inorganic nitrate per day) for at least 2 days prior to testing visits, as well as 2 hours prior to testing visits. It is provided by the same company that produces the concentrated beet root juice shots (James White Drinks) but the placebo version is nitrate-depleted.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BEET IT - Concentrate Beet root juice (nitrate depleted)
Description: Beet It Sport (James White Drinks, Ltd.) each containing 0mg of inorganic nitrate (\~0 mmol) will be consumed twice daily (totalling \~0 mmol of inorganic nitrate per day) for at least 2 days prior to testing visits, as well as 2 hours prior to testing visits. It is provided by the same company that produces the concentrated beet root juice shots (James White Drinks) but the placebo version is nitrate-depleted.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: BEET IT - Concentrate Beet root juice (nitrate depleted)
Description: Beet It Sport (James White Drinks, Ltd.) each containing 0mg of inorganic nitrate (\~0 mmol) will be consumed twice daily (totalling \~0 mmol of inorganic nitrate per day) for at least 2 days prior to testing visits, as well as 2 hours prior to testing visits. It is provided by the same company that produces the concentrated beet root juice shots (James White Drinks) but the placebo version is nitrate-depleted.